Who are NGX-4010's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Capsaicin 8%, Capsaicin Topical Cream, Topical capsaicin, Capsaicine low dose 0.04 %, Qutenza Patch, Intranasal capsaicin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ngx-4010.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

NGX-4010 — Competitive Intelligence Brief

NGX-4010 (NGX-4010) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical analgesic; TRPV1 agonist. Area: Pain Management / Neurology.

phase 3 Topical analgesic; TRPV1 agonist TRPV1 (transient receptor potential vanilloid 1) Pain Management / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

NGX-4010 (NGX-4010) — NeurogesX. NGX-4010 is a topical capsaicin patch that desensitizes nociceptors (pain-sensing nerve fibers) by depleting substance P, reducing localized pain transmission.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NGX-4010 TARGET	NGX-4010	NeurogesX	phase 3	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Capsaicin 8%	Capsaicin 8%	Averitas Pharma, Inc.	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Capsaicin Topical Cream	Capsaicin Topical Cream	Women and Infants Hospital of Rhode Island	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Topical capsaicin	Topical capsaicin	The University of Texas Health Science Center, Houston	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Capsaicine low dose 0.04 %	Capsaicine low dose 0.04 %	University Hospital, Clermont-Ferrand	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Qutenza Patch	Qutenza Patch	M.D. Anderson Cancer Center	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Intranasal capsaicin	Intranasal capsaicin	The University of Texas Health Science Center, Houston	phase 3	TRPV1 agonist / Topical analgesic	TRPV1 (Transient Receptor Potential Vanilloid 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical analgesic; TRPV1 agonist class)

Averitas Pharma, Inc. · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
NeurogesX · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class
Women and Infants Hospital of Rhode Island · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NGX-4010 — Competitive Intelligence Brief. https://druglandscape.com/ci/ngx-4010. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab